King of Prussia, PA, United States of America

Cory R Theberge

USPTO Granted Patents = 20 

 

Average Co-Inventor Count = 4.9

ph-index = 6

Forward Citations = 100(Granted Patents)


Location History:

  • Portsmouth, NH (US) (2001 - 2002)
  • Dover, NH (US) (2002)
  • Elkins Park, PA (US) (2011)
  • King of Prussia, PA (US) (2007 - 2012)
  • Brunswick, ME (US) (2014)

Company Filing History:


Years Active: 2001-2014

Loading Chart...
Loading Chart...
20 patents (USPTO):

Title: Innovations by Cory R. Theberge: Pioneering Therapeutics for CNS Disorders

Introduction: Cory R. Theberge is an accomplished inventor based in King of Prussia, PA. With a remarkable portfolio of 20 patents, he has made significant contributions to the field of pharmaceutical science, particularly in developing therapeutic agents for central nervous system (CNS) disorders. His work showcases the intersection of scientific inquiry and innovative solutions to complex health challenges.

Latest Patents: Among his recent innovations, Theberge has developed compounds targeting phosphodiesterase 10 (PDE10). His patent for Alkoxy Pyrimidine PDE10 Inhibitors details 2-alkoxy pyrimidine compounds that hold promise for treating CNS disorders, including schizophrenia and Huntington's disease. These compounds aim to address issues of striatal hypofunction and basal ganglia dysfunction.

Additionally, he has explored the realm of headache and migraine therapies through his invention of Tricyclic Anilide Spirolactam CGRP Receptor Antagonists. This patent focuses on compounds that serve as antagonists of CGRP receptors, offering potential relief for patients suffering from migraines and cluster headaches. The pharmaceutical compositions derived from these compounds represent a significant advance in headache prevention and treatment strategies.

Career Highlights: Cory R. Theberge has collaborated with leading names in the pharmaceutical industry, including Merck Sharp & Dohme Corporation and Merck & Company, Inc. His extensive experience in these prestigious organizations has equipped him with the expertise necessary to drive innovation in therapeutic development and application.

Collaborations: Throughout his career, Theberge has worked alongside notable colleagues such as Ian M. Bell and C. Blair Zartman. These collaborations have fostered a dynamic environment for academic and practical advancements in the fields of pharmacology and medicinal chemistry.

Conclusion: Cory R. Theberge's contributions to the field of pharmacological innovation reflect a deep commitment to improving the lives of individuals affected by CNS disorders. His patents not only demonstrate his ingenuity as an inventor but also highlight the crucial role of collaboration in advancing medical science. As he continues to develop new therapeutic solutions, Theberge remains a significant figure in the landscape of pharmaceutical invention.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…